Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

A systematic review protocol of timing, efficacy and cost effectiveness of upper limb therapy for motor recovery post-stroke.

Hayward KS, Kramer SF, Thijs V, Ratcliffe J, Ward NS, Churilov L, Jolliffe L, Corbett D, Cloud G, Kaffenberger T, Brodtmann A, Bernhardt J, Lannin NA.

Syst Rev. 2019 Jul 25;8(1):187. doi: 10.1186/s13643-019-1093-6.

2.

Increasing the uptake of stroke upper limb guideline recommendations with occupational therapists and physiotherapists. A qualitative study using the Theoretical Domains Framework.

Jolliffe L, Hoffmann T, Lannin NA.

Aust Occup Ther J. 2019 Oct;66(5):603-616. doi: 10.1111/1440-1630.12599. Epub 2019 Jul 23.

PMID:
31338859
3.

Using audit and feedback to increase clinician adherence to clinical practice guidelines in brain injury rehabilitation: A before and after study.

Jolliffe L, Morarty J, Hoffmann T, Crotty M, Hunter P, Cameron ID, Li X, Lannin NA.

PLoS One. 2019 Mar 13;14(3):e0213525. doi: 10.1371/journal.pone.0213525. eCollection 2019.

4.

Systematic review of clinical practice guidelines to identify recommendations for rehabilitation after stroke and other acquired brain injuries.

Jolliffe L, Lannin NA, Cadilhac DA, Hoffmann T.

BMJ Open. 2018 Feb 28;8(2):e018791. doi: 10.1136/bmjopen-2017-018791. Review.

6.

Assisted or Protected Mealtimes? Exploring the impact of hospital mealtime practices on meal intake.

Young A, Allia A, Jolliffe L, de Jersey S, Mudge A, McRae P, Banks M.

J Adv Nurs. 2016 Jul;72(7):1616-25. doi: 10.1111/jan.12940. Epub 2016 Mar 21.

PMID:
26996998
7.

Strychnine poisoning: gone but not forgotten.

Parker AJ, Lee JB, Redman J, Jolliffe L.

Emerg Med J. 2011 Jan;28(1):84. doi: 10.1136/emj.2009.080879. Epub 2010 Sep 1.

PMID:
20810461
8.

Airway management in the outpatient setting: new devices and techniques.

Jolliffe L, Jackson I.

Curr Opin Anaesthesiol. 2008 Dec;21(6):719-22. doi: 10.1097/ACO.0b013e328316bb57. Review.

PMID:
18997523
9.

Potential involvement of BMP receptor type IB activation in a synergistic effect of chondrogenic promotion between rhTGFbeta3 and rhGDF5 or rhBMP7 in human mesenchymal stem cells.

Xu D, Gechtman Z, Hughes A, Collins A, Dodds R, Cui X, Jolliffe L, Higgins L, Murphy A, Farrell F.

Growth Factors. 2006 Dec;24(4):268-78.

PMID:
17381068
10.

The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases.

Emanuel S, Rugg CA, Gruninger RH, Lin R, Fuentes-Pesquera A, Connolly PJ, Wetter SK, Hollister B, Kruger WW, Napier C, Jolliffe L, Middleton SA.

Cancer Res. 2005 Oct 1;65(19):9038-46.

11.

Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.

Kuo GH, Prouty C, Wang A, Emanuel S, Deangelis A, Zhang Y, Song F, Beall L, Connolly PJ, Karnachi P, Chen X, Gruninger RH, Sechler J, Fuentes-Pesquera A, Middleton SA, Jolliffe L, Murray WV.

J Med Chem. 2005 Jul 28;48(15):4892-909.

PMID:
16033269
12.

Synthesis and identification of [1,3,5]triazine-pyridine biheteroaryl as a novel series of potent cyclin-dependent kinase inhibitors.

Kuo GH, Deangelis A, Emanuel S, Wang A, Zhang Y, Connolly PJ, Chen X, Gruninger RH, Rugg C, Fuentes-Pesquera A, Middleton SA, Jolliffe L, Murray WV.

J Med Chem. 2005 Jul 14;48(14):4535-46.

PMID:
15999992
13.

1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities.

Lin R, Connolly PJ, Huang S, Wetter SK, Lu Y, Murray WV, Emanuel SL, Gruninger RH, Fuentes-Pesquera AR, Rugg CA, Middleton SA, Jolliffe LK.

J Med Chem. 2005 Jun 30;48(13):4208-11.

PMID:
15974571
14.

3-Acyl-2,6-diaminopyridines as cyclin-dependent kinase inhibitors: synthesis and biological evaluation.

Lin R, Lu Y, Wetter SK, Connolly PJ, Turchi IJ, Murray WV, Emanuel SL, Gruninger RH, Fuentes-Pesquera AR, Adams M, Pandey N, Moreno-Mazza S, Middleton SA, Jolliffe LK.

Bioorg Med Chem Lett. 2005 May 2;15(9):2221-4.

PMID:
15837297
15.

Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors.

Kuo GH, Wang A, Emanuel S, Deangelis A, Zhang R, Connolly PJ, Murray WV, Gruninger RH, Sechler J, Fuentes-Pesquera A, Johnson D, Middleton SA, Jolliffe L, Chen X.

J Med Chem. 2005 Mar 24;48(6):1886-900.

PMID:
15771433
16.

rHuEPO and improved treatment outcomes: potential modes of action.

Blackwell K, Gascón P, Sigounas G, Jolliffe L.

Oncologist. 2004;9 Suppl 5:41-7. Review.

17.

A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models.

Emanuel S, Gruninger RH, Fuentes-Pesquera A, Connolly PJ, Seamon JA, Hazel S, Tominovich R, Hollister B, Napier C, D'Andrea MR, Reuman M, Bignan G, Tuman R, Johnson D, Moffatt D, Batchelor M, Foley A, O'Connell J, Allen R, Perry M, Jolliffe L, Middleton SA.

Mol Pharmacol. 2004 Sep;66(3):635-47.

PMID:
15322256
18.

Erytropoietin concentrations in cerebrospinal fluid of nonhuman primates and fetal sheep following high-dose recombinant erythropoietin.

Juul SE, McPherson RJ, Farrell FX, Jolliffe L, Ness DJ, Gleason CA.

Biol Neonate. 2004;85(2):138-44. Epub 2003 Nov 24.

PMID:
14639039
19.

Human recombinant erythropoietin significantly improves tumor oxygenation independent of its effects on hemoglobin.

Blackwell KL, Kirkpatrick JP, Snyder SA, Broadwater G, Farrell F, Jolliffe L, Brizel DM, Dewhirst MW.

Cancer Res. 2003 Oct 1;63(19):6162-5.

20.

Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3beta inhibitors.

Kuo GH, Prouty C, DeAngelis A, Shen L, O'Neill DJ, Shah C, Connolly PJ, Murray WV, Conway BR, Cheung P, Westover L, Xu JZ, Look RA, Demarest KT, Emanuel S, Middleton SA, Jolliffe L, Beavers MP, Chen X.

J Med Chem. 2003 Sep 11;46(19):4021-31.

PMID:
12954055
21.

Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial.

Utset TO, Auger JA, Peace D, Zivin RA, Xu D, Jolliffe L, Alegre ML, Bluestone JA, Clark MR.

J Rheumatol. 2002 Sep;29(9):1907-13.

PMID:
12233885
22.

Arylpiperazine substituted heterocycles as selective alpha(1a) adrenergic antagonists.

Khatuya H, Hutchings RH, Kuo GH, Pulito VL, Jolliffe LK, Li X, Murray WV.

Bioorg Med Chem Lett. 2002 Sep 2;12(17):2443-6.

PMID:
12161153
23.

Novel thiophene derivatives for the treatment of benign prostatic hyperplasia.

Khatuya H, Pulito VL, Jolliffe LK, Li X, Murray WV.

Bioorg Med Chem Lett. 2002 Aug 19;12(16):2145-8.

PMID:
12127524
24.

Erythropoietin induces changes in gene expression in PC-12 cells.

Renzi MJ, Farrell FX, Bittner A, Galindo JE, Morton M, Trinh H, Jolliffe LK.

Brain Res Mol Brain Res. 2002 Jul 15;104(1):86-95.

PMID:
12117554
25.

Novel heterocycles as selective alpha1-adrenergic receptor antagonists.

Li X, McCoy KA, Murray WV, Jolliffe L, Pulito V.

Bioorg Med Chem Lett. 2000 Oct 16;10(20):2375-7.

PMID:
11055359
26.

Design, synthesis and biological evaluation of pyridine-phenylpiperazines: a novel series of potent and selective alpha1a-adrenergic receptor antagonist.

Kuo GH, Prouty C, Murray WV, Pulito V, Jolliffe L, Cheung P, Varga S, Evangelisto M, Shaw C.

Bioorg Med Chem. 2000 Sep;8(9):2263-75.

PMID:
11026539
27.

Synthesis and erythropoietin receptor binding affinities of N,N-disubstituted amino acids.

Connolly PJ, Wetter SK, Murray WV, Johnson DL, McMahon FJ, Farrell FX, Tullai J, Jolliffe LK.

Bioorg Med Chem Lett. 2000 Sep 4;10(17):1995-9.

PMID:
10987435
28.

Erythropoietin mimetic peptides and the future.

Johnson DL, Jolliffe LK.

Nephrol Dial Transplant. 2000 Sep;15(9):1274-7. Review. No abstract available.

PMID:
10978375
29.

An investigation of the uroselective properties of four novel alpha(1a)-adrenergic receptor subtype-selective antagonists.

Pulito VL, Li X, Varga SS, Mulcahy LS, Clark KS, Halbert SA, Reitz AB, Murray WV, Jolliffe LK.

J Pharmacol Exp Ther. 2000 Jul;294(1):224-9.

PMID:
10871316
30.

Novel arylpiperazines as selective alpha1-adrenergic receptor antagonists.

Li X, Murray WV, Jolliffe L, Pulito V.

Bioorg Med Chem Lett. 2000 May 15;10(10):1093-6.

PMID:
10843225
31.

Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.

Kuo GH, Prouty C, Murray WV, Pulito V, Jolliffe L, Cheung P, Varga S, Evangelisto M, Wang J.

J Med Chem. 2000 Jun 1;43(11):2183-95.

PMID:
10841797
32.

In vitro characterization of five humanized OKT3 effector function variant antibodies.

Xu D, Alegre ML, Varga SS, Rothermel AL, Collins AM, Pulito VL, Hanna LS, Dolan KP, Parren PW, Bluestone JA, Jolliffe LK, Zivin RA.

Cell Immunol. 2000 Feb 25;200(1):16-26.

PMID:
10716879
33.

The structure, organization, activation and plasticity of the erythropoietin receptor.

Wilson IA, Jolliffe LK.

Curr Opin Struct Biol. 1999 Dec;9(6):696-704. Review.

PMID:
10607675
34.

Using affinity capillary electrophoresis to study the interaction of the extracellular binding domain of erythropoietin receptor with peptides.

Caldwell GW, McDonnell PA, Masucci JA, Johnson DL, Jolliffe LK.

J Biochem Biophys Methods. 1999 Jul 28;40(1-2):17-25.

PMID:
10481948
35.

New epoetin molecules and novel therapeutic approaches.

Barbone FP, Johnson DL, Farrell FX, Collins A, Middleton SA, McMahon FJ, Tullai J, Jolliffe LK.

Nephrol Dial Transplant. 1999;14 Suppl 2:80-4. Review.

PMID:
10334672
36.

Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide.

Middleton SA, Barbone FP, Johnson DL, Thurmond RL, You Y, McMahon FJ, Jin R, Livnah O, Tullai J, Farrell FX, Goldsmith MA, Wilson IA, Jolliffe LK.

J Biol Chem. 1999 May 14;274(20):14163-9.

37.

Phase I evaluation of humanized OKT3: toxicity and immunomodulatory effects of hOKT3gamma4.

Richards J, Auger J, Peace D, Gale D, Michel J, Koons A, Haverty T, Zivin R, Jolliffe L, Bluestone JA.

Cancer Res. 1999 May 1;59(9):2096-101.

38.

Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation.

Livnah O, Stura EA, Middleton SA, Johnson DL, Jolliffe LK, Wilson IA.

Science. 1999 Feb 12;283(5404):987-90.

39.

An antagonist peptide-EPO receptor complex suggests that receptor dimerization is not sufficient for activation.

Livnah O, Johnson DL, Stura EA, Farrell FX, Barbone FP, You Y, Liu KD, Goldsmith MA, He W, Krause CD, Pestka S, Jolliffe LK, Wilson IA.

Nat Struct Biol. 1998 Nov;5(11):993-1004.

PMID:
9808045
40.

Humanized, nonmitogenic OKT3 antibody, huOKT3 gamma(Ala-Ala): initial clinical experience.

Woodle ES, Bluestone JA, Zivin RA, Jolliffe LK, Auger J, Xu D, Thistlethwaite JR.

Transplant Proc. 1998 Jun;30(4):1369-70. No abstract available.

PMID:
9636555
41.

Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1.

Johnson DL, Farrell FX, Barbone FP, McMahon FJ, Tullai J, Hoey K, Livnah O, Wrighton NC, Middleton SA, Loughney DA, Stura EA, Dower WJ, Mulcahy LS, Wilson IA, Jolliffe LK.

Biochemistry. 1998 Mar 17;37(11):3699-710.

PMID:
9521688
42.

Amino-terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity.

Johnson DL, Farrell FX, Barbone FP, McMahon FJ, Tullai J, Kroon D, Freedy J, Zivin RA, Mulcahy LS, Jolliffe LK.

Chem Biol. 1997 Dec;4(12):939-50.

43.

Increased potency of an erythropoietin peptide mimetic through covalent dimerization.

Wrighton NC, Balasubramanian P, Barbone FP, Kashyap AK, Farrell FX, Jolliffe LK, Barrett RW, Dower WJ.

Nat Biotechnol. 1997 Nov;15(12):1261-5.

PMID:
9359108
44.

Mutagenesis studies of the human erythropoietin receptor. Establishment of structure-function relationships.

Barbone FP, Middleton SA, Johnson DL, McMahon FJ, Tullai J, Gruninger RH, Schilling AE, Jolliffe LK, Mulcahy LS.

J Biol Chem. 1997 Feb 21;272(8):4985-92.

45.

Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A.

Livnah O, Stura EA, Johnson DL, Middleton SA, Mulcahy LS, Wrighton NC, Dower WJ, Jolliffe LK, Wilson IA.

Science. 1996 Jul 26;273(5274):464-71.

PMID:
8662530
46.

Small peptides as potent mimetics of the protein hormone erythropoietin.

Wrighton NC, Farrell FX, Chang R, Kashyap AK, Barbone FP, Mulcahy LS, Johnson DL, Barrett RW, Jolliffe LK, Dower WJ.

Science. 1996 Jul 26;273(5274):458-64.

PMID:
8662529
47.

Identification of a critical ligand binding determinant of the human erythropoietin receptor. Evidence for common ligand binding motifs in the cytokine receptor family.

Middleton SA, Johnson DL, Jin R, McMahon FJ, Collins A, Tullai J, Gruninger RH, Jolliffe LK, Mulcahy LS.

J Biol Chem. 1996 Jun 14;271(24):14045-54.

48.

Humanization and molecular modeling of the anti-CD4 monoclonal antibody, OKT4A.

Pulito VL, Roberts VA, Adair JR, Rothermel AL, Collins AM, Varga SS, Martocello C, Bodmer M, Jolliffe LK, Zivin RA.

J Immunol. 1996 Apr 15;156(8):2840-50.

PMID:
8609403
49.

Refolding, purification, and characterization of human erythropoietin binding protein produced in Escherichia coli.

Johnson DL, Middleton SA, McMahon F, Barbone FP, Kroon D, Tsao E, Lee WH, Mulcahy LS, Jolliffe LK.

Protein Expr Purif. 1996 Feb;7(1):104-13.

PMID:
9172774

Supplemental Content

Loading ...
Support Center